PERSPECTIVE THERAPEUTICS INC (CATX) Stock Price, Quote, News and Overview
NYSEARCA:CATX - NYSE Arca - US46489V3024 - Common Stock - Currency: USD
CATX Quote, Performance and Key Statistics
2.76
-0.08 (-2.82%)
The current stock price of CATX is 2.76 USD. In the past month the price decreased by -23.97%. In the past year, price decreased by -71.25%.
CATX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CATX
Company Profile
Perspective Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Seattle, Washington and currently employs 116 full-time employees. The company went IPO on 2002-05-31. Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The firm has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The company is also developing imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The firm's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. The company has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Company Info
PERSPECTIVE THERAPEUTICS INC
2401 Elliott Avenue, Suite 320
Seattle WASHINGTON US
Employees: 118
Company Website: https://www.perspectivetherapeutics.com/
Investor Relations: https://isoray.com/investor-center/
Phone: 12066760900
PERSPECTIVE THERAPEUTICS INC / CATX FAQ
What is the stock price of PERSPECTIVE THERAPEUTICS INC today?
The current stock price of CATX is 2.76 USD. The price decreased by -2.82% in the last trading session.
What is the ticker symbol for PERSPECTIVE THERAPEUTICS INC stock?
The exchange symbol of PERSPECTIVE THERAPEUTICS INC is CATX and it is listed on the NYSE Arca exchange.
On which exchange is CATX stock listed?
CATX stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for PERSPECTIVE THERAPEUTICS INC stock?
16 analysts have analysed CATX and the average price target is 16.42 USD. This implies a price increase of 495% is expected in the next year compared to the current price of 2.76. Check the PERSPECTIVE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PERSPECTIVE THERAPEUTICS INC worth?
PERSPECTIVE THERAPEUTICS INC (CATX) has a market capitalization of 186.55M USD. This makes CATX a Micro Cap stock.
How many employees does PERSPECTIVE THERAPEUTICS INC have?
PERSPECTIVE THERAPEUTICS INC (CATX) currently has 118 employees.
Is PERSPECTIVE THERAPEUTICS INC (CATX) expected to grow?
The Revenue of PERSPECTIVE THERAPEUTICS INC (CATX) is expected to decline by -25.94% in the next year. Check the estimates tab for more information on the CATX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PERSPECTIVE THERAPEUTICS INC (CATX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CATX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CATX, evaluating the profitability, health, valuation and growth aspects
- PERSPECTIVE THERAPEUTICS INC (CATX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PERSPECTIVE THERAPEUTICS INC (CATX) Sales and EPS estimates to see what analysts future expectations are.
- PERSPECTIVE THERAPEUTICS INC (CATX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PERSPECTIVE THERAPEUTICS INC (CATX) Insider and Institutional Ownership to learn about the owners and their transactions.
- PERSPECTIVE THERAPEUTICS INC (CATX) Stock Chart to make your own analysis
- PERSPECTIVE THERAPEUTICS INC (CATX) Latest news and press-releases to stay up to date.
Does PERSPECTIVE THERAPEUTICS INC (CATX) stock pay dividends?
CATX does not pay a dividend.
What is the Price/Earnings (PE) ratio of PERSPECTIVE THERAPEUTICS INC (CATX)?
PERSPECTIVE THERAPEUTICS INC (CATX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.47).
What is the Short Interest ratio of PERSPECTIVE THERAPEUTICS INC (CATX) stock?
The outstanding short interest for PERSPECTIVE THERAPEUTICS INC (CATX) is 10.07% of its float. Check the ownership tab for more information on the CATX short interest.
CATX Technical Analysis
CATX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CATX. The financial health of CATX is average, but there are quite some concerns on its profitability.
CATX Financial Highlights
Over the last trailing twelve months CATX reported a non-GAAP Earnings per Share(EPS) of -1.47. The EPS decreased by -25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.95% | ||
| ROE | -23.71% | ||
| Debt/Equity | 0 |
CATX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 81% to CATX. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of -2619.93% and a revenue growth -25.94% for CATX